Holen Sie sich die Stockscreener-App
1.425
1.06%
0.015
Schlusskurs vom Vortag:
$1.41
Offen:
$1.41
24-Stunden-Volumen:
71,739
Relative Volume:
0.10
Marktkapitalisierung:
$157.84M
Einnahmen:
$42.51M
Nettoeinkommen (Verlust:
$-116.49M
KGV:
-1.2723
EPS:
-1.12
Netto-Cashflow:
$-120.82M
1W Leistung:
-2.40%
1M Leistung:
+4.01%
6M Leistung:
-72.33%
1J Leistung:
-81.23%
1-Tages-Spanne:
$1.375
$1.4325
1-Wochen-Bereich:
$1.26
$1.546
52-Wochen-Spanne:
$1.11
$12.02
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie TNGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
1.43 | 157.84M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.87 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
609.93 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
650.58 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.93 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.53 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
There is no way Tango Therapeutics Inc (TNGX) can keep these numbers up - Sete News
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - GlobeNewswire
Is Tango Therapeutics Inc (TNGX) worth investing in despite its undervalued state? - uspostnews.com
Tango Therapeutics Inc (TNGX) Stock: A Year of Highs and Lows - investchronicle.com
Insider’s View: Deciphering Tango Therapeutics Inc (TNGX)’s Financial Health Through Ratios - DWinneX
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Geode Capital Management LLC - Defense World
Now Is The Time To Build A Position In Tango Therapeutics Inc (NASDAQ:TNGX) - Marketing Sentinel
Press Release Distribution & PR Platform - ACCESS Newswire
Gaining Ground: Tango Therapeutics Inc (TNGX) Closes Lower at 2.35, Down -0.42 - DWinneX
What is the investor’s view on Tango Therapeutics Inc (TNGX)? - uspostnews.com
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Franklin Resources Inc. - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $12.33 Average PT from Analysts - Defense World
Equities Analysts Offer Predictions for TNGX Q1 Earnings - Defense World
Tango Bypasses IPO Route With SPAC Merger - insights.citeline.com
What is HC Wainwright’s Estimate for TNGX Q1 Earnings? - Defense World
Tango Therapeutics’ (TNGX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Tango Therapeutics stock holds Buy rating, $13 target from H.C. Wainwright - Investing.com Canada
Tango Therapeutics stock holds Buy rating, $13 target from H.C. Wainwright By Investing.com - Investing.com South Africa
Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding - simplywall.st
American Century Companies Inc. Purchases 12,162 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Barbara Weber, M.D., Elected to ITM Supervisory Board - Yahoo
Reviewing Biomea Fusion (NASDAQ:BMEA) and Tango Therapeutics (NASDAQ:TNGX) - Defense World
Tango Therapeutics cuts nearly one-fifth of staff - BioPharma Dive
TNGX’s Wild Ride: Down -55.66% – What’s Next for TNGX? - investchronicle.com
How Will Tango Therapeutics Inc (NASDAQ: TNGX) Perform In Months To Come? - Marketing Sentinel
Swiss National Bank Raises Stock Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Charles Schwab Investment Management Inc. Acquires 26,192 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Bank of New York Mellon Corp Sells 8,715 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics to Highlight Preclinical Data on - GlobeNewswire
Breakthrough: Novel Brain-Penetrant Cancer Drugs Target Previously Untreatable Tumors - Stock Titan
Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials By Investing.com - Investing.com South Africa
Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials - Investing.com
Tango Therapeutics, Inc. (NASDAQ:TNGX) Short Interest Up 18.5% in February - Defense World
Tango Therapeutics executive sells shares worth $43,865 - MSN
Cantor Fitzgerald Issues Negative Forecast for TNGX Earnings - Defense World
Tango Therapeutics (TNGX) Expected to Announce Earnings on Monday - Defense World
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity - MSN
Mesothelioma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough - Simply Wall St
Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint - Yahoo Finance UK
Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks
Tango Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Tango Therapeutics, Inc. SEC 10-K Report - TradingView
Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times
Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Can Tango's Cancer Breakthroughs in Pancreatic and Lung Cancer Outweigh Its Growing Losses? - StockTitan
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tango Therapeutics Inc-Aktie (TNGX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Barry Douglas | General Counsel |
Feb 05 '25 |
Sale |
3.16 |
2,556 |
8,081 |
66,014 |
| Beckman Daniella | Chief Financial Officer |
Feb 04 '25 |
Sale |
2.99 |
4,284 |
12,801 |
154,232 |
| Beckman Daniella | Chief Financial Officer |
Feb 05 '25 |
Sale |
3.16 |
3,948 |
12,481 |
150,284 |
| Crystal Adam | See Remarks |
Feb 04 '25 |
Sale |
2.99 |
7,432 |
22,207 |
165,061 |
| Crystal Adam | See Remarks |
Feb 05 '25 |
Sale |
3.16 |
6,851 |
21,659 |
158,210 |
| Weber Barbara | Chief Executive Officer |
Feb 04 '25 |
Sale |
2.99 |
9,778 |
29,217 |
1,631,264 |
| Weber Barbara | Chief Executive Officer |
Feb 05 '25 |
Sale |
3.16 |
9,013 |
28,494 |
1,622,251 |
| Rothenberg Mace | Director |
Nov 18 '24 |
Buy |
3.78 |
10,000 |
37,800 |
31,250 |
| Rothenberg Mace | Director |
Nov 14 '24 |
Buy |
3.62 |
10,000 |
36,200 |
21,250 |
| EcoR1 Capital, LLC | 10% Owner |
Nov 06 '24 |
Sale |
3.28 |
1,494,558 |
4,896,023 |
11,836,178 |
0.01%
2.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):